Barely Significant
← all excerpts

Open-label study of efgartigimod in seronegative myasthenia gravis.

Ther Adv Neurol Disord · 2025 · PMC12579174 · PMID 41180124

Europe PMCDOI
1
hedged sentence
0.0590
closest p · 1.2× alpha
0.0590
boldest claim

The sentences

showed a trendp = 0.059so close (0.05 < p ≤ 0.1)
None predicted response to treatment, although the baseline MGII showed a trend, with higher MGII values (50.3 ± 13.0) in responders compared with 38.6 ± 4.3 in nonresponders, p = 0.059.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.